Ethel Etchelet

Experience

• 

  Hospital Santa Isabel - SP

  Jan 2003 - Jan 2007

  Residente terapia intensiva
• 

  Hospital Aleman

  Feb 2007 - Jun 2016

  Médica Terapia Intensiva Hospital Aleman

  Médica interna UTI y UT intermediaShock room- Servicio de emergencias

• 

  Swiss Medical Group

  Jul 2008 - Jul 2016

  Médica Terapia Intensiva

  Médica UTI Sanatorio Agote

• 

  IADEIN

  May 2009 - Jan 2012

  Fellow nutrición

  Médica especialista en Nutrición

• 

  Fresenius Kabi

  Aug 2009 - Feb 2012

  Médica nutricionista

  Seguimiento domiciliario de pacientes conectados a Nutrición parenteral post transplante de intestino

• 

  Centro Belgrano Obra Social Luis Pasteur. Consultorios externos

  Nov 2014 - Apr 2023

  Médico especialista
• 

  Medtronic Minimally Invasive Therapies Group

  Jul 2016 - Mar 2023

  Senior Clinical Medtronic
• 

  Pfizer

  Mar 2017 - Mar 2023

  Contribute to the development of the Medical component of the Brand Strategy, and to develop a Medical Plan for: A- Sunitinib- Axitinib LOE and Avelumab + Axitinib, supporting of the Brand Plans. B-Develop and implement oncology therapeutic area specific medical plans and publication plans. Additionally, Avelumab maintenance in urothelial cancer and Talazoparib in prostate cancer.C- Encorafenib in colorectal cancerHistory of Pfizer´s LAUNCHING: Adjuvant Sunitinib- Avelumab +Axitinib kidney cancer- Avelumab maintenance in bladder cancer.Contributing to the management of oncology clinical studies with the cross functional team-Clinical trial department, i.ei: TALAPRO 2 and 3, phase IV clinical studies Enzalutamide + Talazoparib in prostate cancer// BreackWater Encorafenib as 1 st line mCCR in Argentine: proper documentation-questionnaire, feasibility, sites, investigators and logistics.• Leading the management of Grants & Sponsorships ensuring proper documentation, contracts and payment.•Management of LOCAL RWE related to the brands, i.e: Real word evidence Sunitinib 2/1 And AVENUE STUDY Avelumab RWE in LATAM.• Show less • Lunch strategy and launching Avelumab + Axitinib in mRCC. Leading activity alliance Pfizer- Merck.•I run more than 15 conferences in renal and urothelial cancer in less than one year, targeting the most important KOLs in the Latin America Region.•I have also be in charge of the following MA activities such as Preceptorships, Symposia, CME, Ad board, Speaker training, Round tables. i.e: Expert confluence in renal cancer- MD Anderson. Madrid. Dec 2019.•Review of Local Product Documents (Package Inserts). More than nine promotional materials.•Development of Medical and Scientific rationale document to be submitted before the B.H (ANMAT), for the following pad. i.e: Temsirolimus discontinuation, Sunitinib update label, Axitinib update label and Avelumab label.•Work closely with marketing colleagues in designing the scientific support to the marketing campaigns during several POAs. i.e: Five meeting in one year.•Development and review of promotional materials for different molecules and tumor types.i.e: Adjuvant Sunitinib, First line Sunitinib, patient profile, Second line Axitinib- Eficacy and Safety, Sunitinib in special population, Launching Avelumab + Axitinib promotional material and guidance of management.•Run trainings sessions to field force, to commercial and other internal colleagues in mRCC, and Merck Serono colleagues pre launching-launching and post.•Conducted and supervised ad boards and speaker training sessions. Three ad boards in one year. 6 Training sessions in one year.•Review and validate the scientific content of the activities sponsored by Marketing, .i.e: Nine promotional material in one year, two guidance of management, conducted more than 10 round table in one year.•Review of the activities and materials of Added Value programs, speakers selection and engagement al key CME. Specially Avelumab + Axitinib launching (Pfizer- Merck alliance). Show less • As a Medical member, within the Pharmaceutical industry I earned a robust experience in medical affairs roles by running activities such as: MSL Athenaeum (I run more than 40 hospital MSL athenaeum in mRCC in less than one year), targeting the most important KOLs in all the country. developing KOL mapping and engagement, building strong interactions with key stakeholders; i.e: I was in charge of presenting new and stablishing molecules to the medical community from KOLs, head of oncology Deparments, raising stars including GPs and payers (Crizotinib, Palbociclib. Sunitinib, Axitinib)• I was also in charge of the following MA activities such as: Development of Medical and Scientific rationale document to be submitted before the B.H (ANMAT), for the following pad. i.e: Bosutinib, Gemtuzumab, Inotuzumab.• Work closely with marketing colleagues in designing the scientific support to the marketing campaigns during several POAs.• Review of the activities and materials of Added Value programs, speakers selection and engagement al key CME in pre launchin and adjuvant Sunitinib launching.• Clinical Research/Early experience: CUP. I manage of supervise myself 3 compassionate use programs. It includes not only providing access to patients in need, but also a chance to educate physicians on the appropriate usage of new experimental products. Show less

  • Regional Champion GU

    Mar 2020 - Mar 2023

  • Medical Manager GU Y COLORRECTAL cancer at PFizer

    Jun 2019 - Mar 2023

  • Oncology Medical Manager Renal Cancer.

    May 2019 - Mar 2020

  • Medical Scientific liaison oncology

    Mar 2017 - Jun 2019
• 

  Adium

  Apr 2023 - now

  Médica especialista